- Trials with a EudraCT protocol (26)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
26 result(s) found for: Parasitic infections.
Displaying page 1 of 2.
EudraCT Number: 2015-001226-42 | Sponsor Protocol Number: MEBENDAZOLGAI3002 | Start Date*: 2015-04-09 | |||||||||||
Sponsor Name:Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |||||||||||||
Full Title: An Open-Label, Single-Dose Study to Assess the Safety of 500-mg Mebendazole Chewable Formulation in Children 2 to 10 Years of Age, Inclusive | |||||||||||||
Medical condition: Soil-transmitted helminth (STH) infections | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001938-96 | Sponsor Protocol Number: PGLIT2016 | Start Date*: 2016-12-22 |
Sponsor Name:Helsinki University Central Hospital | ||
Full Title: Treatment of Giardia lamblia infections in children: randomized open-labeled trial comparing rectal metronidazole with oral tinidazole | ||
Medical condition: Symptomatic Giardia lamblia infections in children | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: FI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004494-27 | Sponsor Protocol Number: 5020DERM-2018 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Landeskrankenhaus Salzburg | ||||||||||||||||||
Full Title: pilotstudy- efficacy of infectoscab 5% creme in patients with scabies | ||||||||||||||||||
Medical condition: Scabies | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000728-24 | Sponsor Protocol Number: MEBENDAZOLGAI3003 | Start Date*: 2016-03-01 |
Sponsor Name: Janssen Research & Development, LLC | ||
Full Title: A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment o... | ||
Medical condition: Helminth infections | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-002723-16 | Sponsor Protocol Number: PREMIVER | Start Date*: 2018-04-20 |
Sponsor Name:Universitaetsklinikum Tuebingen | ||
Full Title: Evaluation of the potential anti-malarial effect of ivermectin: a controlled human malaria infection trial | ||
Medical condition: In spite of remarkable progress over the last 15 years, malaria continues to be a major public health problem in the developing world with an estimated 214 million cases and 438.000 deaths in 2014.... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000322-21 | Sponsor Protocol Number: TIP5 | Start Date*: 2012-05-29 |
Sponsor Name:Sanaria Inc. | ||
Full Title: Controlled human malaria infection after immunization with cryopreserved Plasmodium falciparum sporozoites under chloroquine prophylaxis | ||
Medical condition: Controlled human malaria infection after immunization with cryopreserved Plasmodium falciparum sporozoites under chloroquine prophylaxis. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-024657-36 | Sponsor Protocol Number: DSR-01 | Start Date*: 2011-05-17 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Statens Serum Institut | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Metronidazol for the treatment of dientamoebiasis in children in Denmark – A randomized, placebo-controlled, double-blinded clinical trial. | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Presumed symptomatic gastrointestinal infection with the protozoan Dientamoeba fragilis. | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002255-15 | Sponsor Protocol Number: ST3073-ST3074-DM-12-002 | Start Date*: 2014-11-04 |
Sponsor Name:Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | ||
Full Title: A phase II, open-label, multicentre, pharmacokinetic, pharmacodynamics and safety study of a new paediatric eurartesim dispersible formulation and crushed film coated eurartesim tablet, in infant p... | ||
Medical condition: Uncomplicated Plasmodium falciparum malaria | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-004523-36 | Sponsor Protocol Number: CVac-Tü3 | Start Date*: 2019-04-17 | |||||||||||
Sponsor Name:University Clinics Tübingen | |||||||||||||
Full Title: Safety and protective efficacy of a simplified Plasmodium falciparum sporozoite Chemoprophylaxis Vaccine (PfSPZ-CVac) regimen in healthy malaria-naïve adults in Germany | |||||||||||||
Medical condition: Immunization of healthy volunteers against P. falciparum infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-004143-27 | Sponsor Protocol Number: STRONG-FIX | Start Date*: 2023-09-14 | |||||||||||
Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | |||||||||||||
Full Title: Randomized non-inferiority clinical trial to evaluate the efficacy of a single fixed dose of 18 mg ivermectin for the treatment of uncomplicated strongyloidiasis | |||||||||||||
Medical condition: Strongyloidiasis is caused by a parasite that is globally distributed in tropical and sub-tropical areas. Most patients with strongyloidiasis are asymptomatic or have mild symptoms with gastrointes... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005852-33 | Sponsor Protocol Number: CCOA566B2306 | Start Date*: 2016-04-11 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An open-label, single-arm study to evaluate the efficacy, safety and PK of artemether-lumefantrine Dispersible Tablet in the treatment of acute uncomplicated Plasmodium falciparum malaria in infant... | |||||||||||||
Medical condition: The purpose of the study is to obtain efficacy, safety and pharmacokinetic (PK) data following treatment with artemether-lumefantrine dispersible tablet in infants < 5 kg of body weight (BW) with u... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000290-20 | Sponsor Protocol Number: 204889 | Start Date*: 2017-09-22 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: Phase IIb randomized, open-label, controlled, multi-center study of the efficacy, safety and immunogenicity of GSK Biologicals’ candidate malaria vaccine RTS,S/AS01E evaluating schedules with or wi... | |||||||||||||
Medical condition: Healthy volunteers (primary immunization against malaria disease caused by Plasmodium falciparum) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001333-14 | Sponsor Protocol Number: CCOA566B2303 | Start Date*: 2012-03-09 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, investigator-blinded, multicenter, parallel group study to compare efficacy, safety and tolerability of Coartem® dispersible tablet formulation vs. Coartem® 6-dose crushed tablet in t... | |||||||||||||
Medical condition: This study will evaluate the safety and efficacy of artemether-lumefantrine against uncomplicated malaria caused by Plasmodium falciparum in children. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004461-85 | Sponsor Protocol Number: CCOA556B2401 | Start Date*: 2016-04-06 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A cluster randomized, single-centre, controlled, parallel,12-month prospective study and additional 12-month follow-up in Africa of malaria incidence in a community setting following systematic tre... | |||||||||||||
Medical condition: This study assessed the impact of the systematic detection by Rapid Diagnostic Test (RDT) and treatment of asymptomatic carriers of malaria parasites (P. falciparum) with COA566 on the number of cl... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005735-40 | Sponsor Protocol Number: BCG-EHMI | Start Date*: 2016-03-29 | |||||||||||||||||||||
Sponsor Name:Radboud university medical center | |||||||||||||||||||||||
Full Title: Safety and protective efficacy of BCG vaccination against controlled human malaria infection | |||||||||||||||||||||||
Medical condition: Plasmodium faciparum malaria prevention | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-004163-21 | Sponsor Protocol Number: A0661157 | Start Date*: 2015-04-06 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: Phase 2/3, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Children In Africa | |||||||||||||
Medical condition: Malaria | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002022-41 | Sponsor Protocol Number: CHAGAS-EVOL I | Start Date*: 2011-10-13 | |||||||||||
Sponsor Name:Fundación para la Investigación Biomédica del Hospital Ramón y Cajal | |||||||||||||
Full Title: Assessment of Therapeutic Response to Benznidazole in patients with Chronic Chagas Disease by Measuring Plasma Parasite Load and the Specific Immune Response against Trypanosoma cruzi. A Randomized... | |||||||||||||
Medical condition: Chagas disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002900-34 | Sponsor Protocol Number: CINE-BENZ | Start Date*: 2012-03-07 | |||||||||||
Sponsor Name:CRESIB- International Research Center in Health of Barcelona | |||||||||||||
Full Title: Population Pharmacokinetics in Benznidazol-treated adults with Chronic Chagas Disease. Benznidazol Pharmacokinetics and adverse reactions relationship. | |||||||||||||
Medical condition: The study will be held in 50 patients with Chronic Chagas Disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000599-38 | Sponsor Protocol Number: RC20_0007 | Start Date*: 2020-11-26 | |||||||||||
Sponsor Name:NANTES CHU | |||||||||||||
Full Title: A phase I/II study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of FR104, a novel antagonist pegylated anti-CD28 Fab’ antibody fragment in de novo renal trans... | |||||||||||||
Medical condition: Kidney transplant | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003583-27 | Sponsor Protocol Number: CKAF156A2203 | Start Date*: 2024-10-15 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A Phase 2 interventional, multicenter, randomized, open-label study in three age-descending cohorts to evaluate efficacy, safety and tolerability of KAF156 and Lumefantrine-SDF combination in the t... | |||||||||||||
Medical condition: Plasmodium Falciparum Malaria | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
